Compositions and methods for ophthalmic and/or other applications
Particles, compositions, and methods that aid particle transport in mucus are provided. The particles, compositions, and methods may be used, in some instances, for ophthalmic and/or other applications. In some embodiments, the compositions and methods may involve modifying the surface coatings of particles, such as particles of pharmaceutical agents that have a low aqueous solubility. Such compositions and methods can be used to achieve efficient transport of particles of pharmaceutical agents though mucus barriers in the body for a wide spectrum of applications, including drug delivery, imaging, and diagnostic applications. In certain embodiments, a pharmaceutical composition including such particles is well-suited for ophthalmic applications, and may be used for delivering pharmaceutical agents to the front of the eye and/or the back of the eye.
1. A topical pharmaceutical composition comprising:
(A) a plurality of coated nanoparticles, each coated nanoparticle comprising:
(i) a core particle comprising a corticosteroid, wherein the corticosteroid constitutes at least 80 wt % of the core particle by weight, and
(ii) a mucus penetration-enhancing coating surrounding the core particle, the mucus penetration-enhancing coating comprising
a) a triblock copolymer comprising a hydrophilic block-hydrophobic block-hydrophilic block configuration, wherein the hydrophobic block has a molecular weight of at least about 2 kDa, and the hydrophilic blocks constitute at least about 15 wt % of the triblock copolymer, or
b) a polysorbate,
wherein the mucus penetration-enhancing coating is present on the outer surface of the core particle at a density of at least 0.01 molecules/nm 2 ; and
(B) one or more ophthalmically acceptable carriers, additives, and/or diluents;
wherein the mucus penetration-enhancing coating is present in the pharmaceutical composition in an amount of between about 0.001% and about 5% by weight.
2. The topical pharmaceutical composition of claim 1 , wherein the mucus-penetration-enhancing coating is non-covalently adsorbed to the core particle.
3. The topical pharmaceutical composition of claim 1 , wherein the corticosteroid is present in the pharmaceutical composition in an amount between about 0.01% and about 5% by weight in total.
4. The topical pharmaceutical composition of claim 1 , wherein the topical pharmaceutical composition is a topical suspension.
5. The topical pharmaceutical composition of claim 1 , wherein the plurality of coated particles have an average smallest cross-sectional dimension of less than about 1 micron.
6. The topical pharmaceutical composition of claim 1 , wherein the mucus penetration-enhancing coating is present on the surfaces of the coated particles at a density of at least about 0.1 molecules per nanometer squared.
7. The topical pharmaceutical composition of claim 1 , wherein the mucus penetration-enhancing coating comprises a triblock copolymer comprising a hydrophilic block-hydrophobic block-hydrophilic block configuration, wherein the hydrophobic block has a molecular weight of at least about 2 kDa, and the hydrophilic blocks constitute at least about 15 wt % of the triblock copolymer, wherein the hydrophobic block associates with the surface of the core particle, and wherein the hydrophilic block is present at the surface of the coated particle and renders the coated particle hydrophilic.
8. The topical pharmaceutical composition of claim 7 , wherein the hydrophilic blocks of the triblock copolymer constitute at least about 30 wt % of the triblock polymer and less than or equal to about 80 wt % of the triblock copolymer.
9. The topical pharmaceutical composition of claim 7 , wherein the hydrophobic block portion of the triblock copolymer has a molecular weight of at least about 3 kDa and less than or equal to about 8 kDa.
10. The topical pharmaceutical composition of claim 7 , wherein the triblock copolymer is poly(ethylene oxide)-poly(propylene oxide)-poly(ethylene oxide) or poly(ethylene glycol)-poly(propylene oxide)-poly(ethylene glycol).
11. The topical pharmaceutical composition of claim 1 , wherein the mucus penetration-enhancing coating has a molecular weight of at least about 4 kDa.
12. The topical pharmaceutical composition of claim 1 , wherein the polydispersity index of the mucus-penetrating pharmaceutical composition is less than or equal to about 0.5.
13. A method of treating an ocular condition in a subject, the method comprising:
administering the topical pharmaceutical composition of claim 1 to an eye of a subject;
wherein the ocular condition is selected from inflammation, macular degeneration, macular edema, uveitis, dry eye, blepharitis, and cystoid macular edema.